| |
| |
| Exchange: |
Over The Counter |
| Security
Type: |
Common |
| Shares
Out: |
5,670,000 |
| Market
Cap: |
970.14(K) |
| Last
Volume: |
38,510 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.1711 - $0.1711 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Diffusion Pharmaceuticals is a clinical stage biotechnology company. Co. is developing its primary product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC). TSC is designed to selectively target and re-oxygenate the micro-environment of hypoxic cells, and can potentially be used in various indications, including stroke, oncology and cardiovascular disease. Co.'s oncology program targets TSC against treatment-resistant brain cancer. In addition to the TSC programs, Co. is exploring alternatives to capitalize upon its product candidate RES-529, a PI3K/Akt/mTOR pathway inhibitor for age-related macular degeneration.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
14,606 |
14,606 |
18,839 |
19,839 |
| Total Buy Value |
$107,670 |
$107,670 |
$143,481 |
$161,641 |
| Total People Bought |
3 |
3 |
3 |
3 |
| Total Buy Transactions |
3 |
3 |
4 |
5 |
| Total Shares Sold |
0 |
0 |
0 |
36 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2025-08-17 |
2025-05-16 |
2024-11-15 |
2023-11-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gregoire Sylvie |
Director |
• • • |
2025-11-12 |
4 |
B |
$7.35 |
$40,815 |
D/D |
5,553 |
1,467,131 |
3.92 |
- |
|
| Elder William Robert |
CFO, GC & Secretary |
• • – |
2025-11-12 |
4 |
B |
$7.44 |
$26,040 |
D/D |
3,500 |
9,000 |
2.74 |
- |
|
| Alam John J |
CEO & President |
• • • |
2025-11-12 |
4 |
B |
$7.35 |
$40,815 |
D/D |
5,553 |
1,467,131 |
3.23 |
- |
|
| Elder William Robert |
CFO, GC & Secretary |
• • – |
2025-05-14 |
4 |
B |
$8.46 |
$35,811 |
D/D |
4,233 |
5,500 |
2.74 |
- |
|
| Elder William Robert |
CFO & GC |
• • – |
2024-08-27 |
4 |
B |
$18.16 |
$18,160 |
D/D |
1,000 |
1,267 |
2.74 |
- |
|
| Boger Joshua S |
Director |
• • • |
2024-02-26 |
4 |
S |
$0.00 |
$0 |
I/I |
(36) |
840,451 |
|
- |
|
| Boger Joshua S |
Director |
• • • |
2024-02-26 |
4 |
OE |
$0.00 |
$0 |
I/I |
495,995 |
840,487 |
|
- |
|
| Gregoire Sylvie |
Director |
• • • |
2023-11-09 |
4 |
GD |
$0.00 |
$0 |
D/D |
10,000 |
732,039 |
|
- |
|
| Alam John J |
CEO & President |
• • • |
2023-11-09 |
4 |
GD |
$0.00 |
$0 |
D/D |
12,500 |
729,539 |
|
- |
|
| Hollingsworth Jane H |
Director |
• • – |
2023-08-31 |
4 |
D |
$0.00 |
$0 |
D/D |
(45) |
898 |
|
- |
|
| Hollingsworth Jane H |
Director |
• • – |
2023-08-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
122 |
943 |
|
- |
|
| Zavrl Frank |
Director |
– • – |
2023-08-16 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
246,365 |
|
- |
|
| Zavrl Frank |
Director |
– • – |
2023-08-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
106,644 |
|
- |
|
| Alam John J |
CEO and PresidentOfficer |
• • • |
2023-08-16 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
742,039 |
|
- |
|
| Alam John J |
CEO and PresidentOfficer |
• • • |
2023-08-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
742,039 |
|
- |
|
| Blackburn Kelly |
VP, Clinical DevelopmentOffice |
• – – |
2023-08-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
13,674 |
|
- |
|
| Lanchoney Diana M |
Director |
• • – |
2023-06-30 |
4 |
D |
$0.00 |
$0 |
D/D |
(85) |
294 |
|
- |
|
| Lanchoney Diana M |
Director |
• • – |
2023-06-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
232 |
379 |
|
- |
|
| Hollingsworth Jane H |
Director |
• • – |
2023-05-31 |
4 |
D |
$0.00 |
$0 |
D/D |
(68) |
1,231 |
|
- |
|
| Hollingsworth Jane H |
Director |
• • – |
2023-05-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
183 |
1,299 |
|
- |
|
| Hollingsworth Jane H |
Director |
• • – |
2023-02-28 |
4 |
D |
$0.00 |
$0 |
D/D |
(68) |
1,116 |
|
- |
|
| Hollingsworth Jane H |
Director |
• • – |
2023-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
183 |
1,184 |
|
- |
|
| Cobuzzi Robert Joseph Jr. |
President & CEO |
• • – |
2023-01-31 |
4 |
D |
$0.00 |
$0 |
D/D |
(121) |
1,616 |
|
- |
|
| Cobuzzi Robert Joseph Jr. |
President & CEO |
• • – |
2023-01-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
327 |
1,737 |
|
- |
|
| Hollingsworth Jane H |
Director |
• • – |
2022-11-30 |
4 |
D |
$0.00 |
$0 |
D/D |
(68) |
1,001 |
|
- |
|
62 Records found
|
|
Page 1 of 3 |
|
|
